Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505471 | 0.90 | P2RX7 (0.49) | P2RX7C5AR1CXCR4ALDH1A1MEN1 | |
| SCHEMBL4523847 | 0.85 | LMNA (0.48) | MEN1KMT2AROCK2KDM4E | |
| SCHEMBL14177628 | 0.85 | CYP26A1 (0.46) | CYP26A1CYP24A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4514642 | 0.83 | P2RX7 (0.47) | P2RX7C5AR1CXCR4ALDH1A1MEN1 | |
| SCHEMBL4509814 | 0.78 | SIGMAR1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14177625 | 0.78 | ALDH1A1 (0.50) | CXCR4ALDH1A1KMT2AROCK2 | |
| SCHEMBL14177631 | 0.78 | ALDH1A1 (0.47) | P2RX7CXCR4ALDH1A1ROCK2KDM4E | |
| SCHEMBL4510232 | 0.77 | P2RX7 (0.58) | P2RX7ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4513457 | 0.76 | TNKS (0.43) | CYP26A1CYP24A1MEN1KMT2AKDM4E | |
| SCHEMBL4508462 | 0.75 | P2RX7 (0.44) | P2RX7CXCR4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | P2RX7 3946/4885CYP26A1 66/4885CYP24A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.